Replies to post #159994 on Biotech Values

[JJM760]

Berger has been adamant in his belief that the AE's have been due to the fact that most of the patients have been previously treated with 2 other TKI's. Hopefully there is no dosing issue. If there is, Ariad is objective and ahead of it.

[DewDiligence]

FDA modifies Jakafi label with respect to dosing:

http://finance.yahoo.com/news/jakafi-ruxolitinib-prescribing-information-updated-211500260.html

The prescribing information for Jakafi now includes a new recommended starting dose of 5 mg twice daily of Jakafi for patients with baseline platelet counts between 50–100 x 109/L (50,000 to 100,000) and the flexibility for subsequent dose modifications based on safety and efficacy.